StreetInsider.com News Articles

Form 4 Metagenomi Therapeutics, For: Jun 09 Filed by: Reid Laurence

Thu, 11 Jun 2026 14:32:00 -0400

si-local-file:///var/storage/secattach/20260611/26635111.html

Form 4 Metagenomi Therapeutics, For: Jun 09 Filed by: Reid Laurence

Thu, 11 Jun 2026 14:32:00 -0400

si-local-file:///var/storage/secattach/20260611/26635111.html

Form 4 Metagenomi Therapeutics, For: Jun 09 Filed by: Dere Willard H

Thu, 11 Jun 2026 14:23:00 -0400

si-local-file:///var/storage/secattach/20260611/26635072.html

Form 4 Metagenomi Therapeutics, For: Jun 09 Filed by: Dere Willard H

Thu, 11 Jun 2026 14:23:00 -0400

si-local-file:///var/storage/secattach/20260611/26635072.html

Form 4 Metagenomi Therapeutics, For: Jun 09 Filed by: BJERKHOLT ERIC

Thu, 11 Jun 2026 13:49:00 -0400

si-local-file:///var/storage/secattach/20260611/26634919.html

Form 4 Metagenomi Therapeutics, For: Jun 09 Filed by: BJERKHOLT ERIC

Thu, 11 Jun 2026 13:49:00 -0400

si-local-file:///var/storage/secattach/20260611/26634919.html

Form 4 Metagenomi Therapeutics, For: Jun 09 Filed by: Eckhardt Juergen

Thu, 11 Jun 2026 13:38:00 -0400

si-local-file:///var/storage/secattach/20260611/26634878.html

Form 4 Metagenomi Therapeutics, For: Jun 09 Filed by: Eckhardt Juergen

Thu, 11 Jun 2026 13:38:00 -0400

si-local-file:///var/storage/secattach/20260611/26634878.html

Form 4 Metagenomi Therapeutics, For: Jun 05 Filed by: Wapnick Pamela

Wed, 10 Jun 2026 11:24:00 -0400

si-local-file:///var/storage/secattach/20260610/26628568.html

Form 4 Metagenomi Therapeutics, For: Jun 05 Filed by: Wapnick Pamela

Wed, 10 Jun 2026 11:24:00 -0400

si-local-file:///var/storage/secattach/20260610/26628568.html

Form 4 Metagenomi Therapeutics, For: Jun 05 Filed by: Irish Jian

Wed, 10 Jun 2026 11:22:00 -0400

si-local-file:///var/storage/secattach/20260610/26628550.html

Form 4 Metagenomi Therapeutics, For: Jun 05 Filed by: Irish Jian

Wed, 10 Jun 2026 11:22:00 -0400

si-local-file:///var/storage/secattach/20260610/26628550.html

Form 4 Metagenomi Therapeutics, For: Jun 05 Filed by: Wein Matthew

Wed, 10 Jun 2026 11:20:00 -0400

si-local-file:///var/storage/secattach/20260610/26628537.html

Form 4 Metagenomi Therapeutics, For: Jun 05 Filed by: Wein Matthew

Wed, 10 Jun 2026 11:20:00 -0400

si-local-file:///var/storage/secattach/20260610/26628537.html

Form 8-K Metagenomi Therapeutics, For: Jun 09

Wed, 10 Jun 2026 06:01:00 -0400

si-local-file:///var/storage/secattach/20260610/26625994.html

Form 8-K Metagenomi Therapeutics, For: Jun 09

Wed, 10 Jun 2026 06:01:00 -0400

si-local-file:///var/storage/secattach/20260610/26625994.html

Metagenomi Therapeutics, Inc. to Present at the Jefferies Global Healthcare Conference

Thu, 28 May 2026 08:00:00 -0400

EMERYVILLE, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Metagenomi Therapeutics, Inc. (Nasdaq: MGX) (the “Company”), an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients, today announced that Jian Irish, Ph.D., M.B.A., President and Chief Executive Officer of the Company, will participate in a fireside chat at the Jefferies Global Healthcare Conference, being held in New York, NY, on Thursday, June 4, 2026, at 7:35 a.m. ET.

The fireside chat presentation will be made available on the “News & Events” page in the Investors section of the Company’s

Metagenomi Therapeutics, Inc. to Present at the Jefferies Global Healthcare Conference

Thu, 28 May 2026 08:00:00 -0400

The fireside chat presentation will be made available on the “News & Events” page in the Investors section of the Company’s

Metagenomi Inc (MGX) PT Lowered to $9 at Wells Fargo

Tue, 12 May 2026 05:43:53 -0400

Wells Fargo analyst Yanan Zhu lowered the price target on Metagenomi Inc (NASDAQ: MGX) to $9.00 (from $12.00) while maintaining a Overweight rating.

The analyst comments "Following the company's 1Q update, we note that MGX-001 for Hemophilia A continues to progress on track, with an IND filing anticipated in 4Q26 and initiation of a Ph1/2 trial in 2027. 1Q26 earnings results. MGX reported 1Q26 operating results today. Net loss per share was ($0.61) vs. consensus of ($0.55). MGX ended the quarter with a cash position of $140MM, which is expected to fund operations through 4Q27. Our 2026/2027 EPS estimates are now

Metagenomi Inc (MGX) PT Lowered to $9 at Wells Fargo

Tue, 12 May 2026 05:43:53 -0400

Wells Fargo analyst Yanan Zhu lowered the price target on Metagenomi Inc (NASDAQ: MGX) to $9.00 (from $12.00) while maintaining a Overweight rating.

Metagenomi, Inc. (MGX) Tops Q1 EPS by 17c

Mon, 11 May 2026 17:40:51 -0400

Metagenomi, Inc. (NASDAQ: MGX) reported Q1 EPS of ($0.61), $0.17 better than the analyst estimate of ($0.78). Revenue for the quarter came in at $1.25 million.

For earnings history and earnings-related data on Metagenomi, Inc. (MGX) click here.

Form 10-Q Metagenomi Therapeutics, For: Mar 31

Mon, 11 May 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260511/26469161.html

Form 10-Q Metagenomi Therapeutics, For: Mar 31

Mon, 11 May 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260511/26469161.html

Form 8-K Metagenomi Therapeutics, For: May 11

Mon, 11 May 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260511/26469106.html

Form 8-K Metagenomi Therapeutics, For: May 11

Mon, 11 May 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260511/26469106.html